Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
In brief
The purpose of this study is to determine whether lozenges containing interferon-alpha can reduce the frequency and severity of coughing in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
Key facts
- Study ID
- NCT00690885
- Run by
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- People needed
- 1
- Starts
- 2008-06-01
- Expected to finish
- 2012-04-01
- Last updated by the study team
- 2012-04-24
Who can join
Age: 40 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- For all patients
- history of clinically significant chronic cough for > 3 months
- For COPD patients
- >40 years of age
- 20-pack-year history of smoking
- GOLD classification of Stage 1 or higher
- For IPF patients
- > 50 years of age
- history of unexplained dyspnea on exertion of > 3 months
- exhibits coughing and bilateral, basilar, inspiratory crackles on physical exam
- presents as being in a stable phase of IPF
- lung biopsy or HRCT indicative of IPF
You may not qualify if…
- ACE inhibitor use
- GERD
- current cancer or history of lung cancer
- non-ambulatory
- hospitalized in the previous 12 months for heart failure
Where it is running
- Texas Tech University Health Sciences Center — Lubbock, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.